Fig. 3From: Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b studyKaplan–Meier estimates of progression-free survival (a) and overall survival (b) according to treatment groupBack to article page